Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 8249 pages

Showing 101 - 150


FDA Approves Gilteritinib for Relapsed or Refractory FLT3-Mutated AML

Today, the U.S. Food and Drug Administration (FDA) approved gilteritinib (Xospata) for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. The FDA also approved an expanded indication for a companion ...

First Rituximab Biosimilar for Non-Hodgkin Lymphoma Approved by FDA

Today, the U.S. Food and Drug Administration (FDA) approved rituximab-abbs (Truxima) as the first biosimilar to rituximab (Rituxan) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma to be used as a single agent or in combination with chemotherapy. Rituximab-abbs is ...

EORTC-NCI-AACR: Investigational Anti-HER2 Therapy in HER2-Expressing Solid Tumors

An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown antitumor activity in a number of cancers, including those of the esophagus, stomach, and bowel. Updated results from a phase I clinical trial of the treatment, called...

EORTC-NCI-AACR: Genomic Testing in Breast Cancer May Enhance Personalized Treatment: Update of I-SPY 2

New results from the long-running I-SPY 2 trial, which aimed to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, demonstrated the usefulness of two genomic tests. Laura van ‘t Veer, PhD, leader of the Breast Oncology Program at the...

hepatobiliary cancer
gastrointestinal cancer

EORTC-NCI-AACR: Dabrafenib Plus Trametinib Active in Some BRAF V600E–Mutated Gastrointestinal Cancers

In a late-breaking presentation at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Zev Wainberg, MD, reported on results from a phase II international clinical trial of dabrafenib (Tafinlar) plus trametinib (Mekinist), which showed some activity in 36 patients ...

FDA Approves Venetoclax Combination for Adults With AML

On November 21, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to venetoclax (Venclexta) in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older or...

FDA Approves Larotrectinib for Solid Tumors With NTRK Gene Fusions

On November 26, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to larotrectinib (Vitrakvi) for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, whose...

leukemia

A Single CAR T Cell Cured My Chronic Lymphocytic Leukemia

The combination of symptoms I began experiencing in the spring of 2007, including night sweats so severe they woke me from a sound sleep and midline chest wall swelling so extreme I needed a larger shirt size, drove me to seek immediate medical attention. A series of imaging and blood tests...

issues in oncology
genomics/genetics
breast cancer

ADVISE PATIENTS ABOUT THE IMPLICATIONS OF RACIAL DISPARITIES FOR BREAST CANCER SCREENING

“BLACK WOMEN are more likely to develop breast cancer at a younger age, compared with white American women, and at all ages, younger and older individuals are more likely to develop triple-negative breast cancers,” Lisa A. Newman, MD, MPH, told The ASCO Post. “So, I think it is very clear that if...

issues in oncology
breast cancer
genomics/genetics

Obligation to Evaluate Racial/Ethnic Features That May Affect Outcomes for Patients With Breast Cancer

"WE ABSOLUTELY have an obligation to evaluate all of the features describing our patients with cancer when we are trying to figure out why some patients do better than others,” Lisa A. Newman, MD, MPH, reminded the nearly 700 participants at the 2018 Lynn Sage Breast Cancer Symposium, hosted by...

A Pediatric Oncologist Recounts 7 Years at a Hospital in Jerusalem

Elisha Waldman, MD, is a pediatric oncologist and Associate Chief in the Division of Palliative Care at the Ann and Robert H. Lurie Children’s Hospital in Chicago. He grew up in a Connecticut suburb, the son of a conservative rabbi. Early on, Dr. Waldman majored in religious studies and felt...

Founder of the Harvard Stem Cell Institute Relates the History of Cancer Research

Cancer memoirs are generally written by people who have an intimate relationship with the disease, mostly survivors, sometimes by those who are dying while writing, such as the breathtaking book, The Bright Hour: A Memoir of Living and Dying, by the poet Nina Riggs. Once in a while, a scientist or...

hepatobiliary cancer

FDA Approves Pembrolizumab for Hepatocellular Carcinoma Previously Treated With a Kinase Inhibitor

ON NOVEMBER 9, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for patients with hepatocellular carcinoma who have been previously treated with the kinase inhibitor sorafenib (Nexavar). KEYNOTE-224 APPROVAL WAS based on KEYNOTE-224, a...

integrative oncology

Probiotics

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Shelly Latte-Naor, MD, and Jyothirmai Gubili, MS, explore some of the beneficial effects attributed ...

issues in oncology

Focus on the Rocky Mountain Oncology Society

Formed in 1991, the Rocky Mountain Oncology Society (RMOS), a Chapter Member of the Association of Community Cancer Centers (ACCC) and State Affiliate of ASCO, serves as the voice for Colorado’s multidisciplinary cancer care teams and the patients they serve. Representing the common interests of...

Michael A. Caligiuri, MD, President of City of Hope National Medical Center, Elected to National Academy of Medicine

MICHAEL A . CALIGIURI, MD, President of City of Hope National Medical Center, and Deana and Steve Campbell Physician-in-Chief Distinguished Chair, has been elected to the National Academy of Medicine, one of the highest honors in the fields of health and medicine. Membership in the Academy...

At Sea

The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...

Six Hospital Systems Launch Research Center on Symptom Management

SIX HOSPITAL systems across the country are launching a new research collaboration to improve the reporting and management of cancer treatment–related symptoms. The initiative, known as the SIMPRO Research Center, will integrate the use of patient-reported outcomes into the routine practice of...

ASH Honors Freda K. Stevenson, DPhil, and Brunangelo Falini, MD, With 2018 Henry M. Stratton Medal

THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) will recognize Freda K. Stevenson, DPhil, of the University of Southampton and Southampton University Hospitals in the United Kingdom, and Brunangelo Falini, MD, of the University of Perugia and the Institute of Hematology and Bone Marrow Transplantation...

ASH Honors Cage S. Johnson, MD, and José A. López, MD, With Award for Leadership in Promoting Diversity

DURING THE 2018 American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego this December, ASH will honor Cage S. Johnson, MD, Professor Emeritus of Medicine, Physiology, and Biophysics at the University of Southern California, and José A. López, MD, Professor of Medicine...

When Illness and Culture Collide

“‘Sickness’ is what is happening to the patient. Listen to him. Disease is what is happening to science and to populations.” —Lawrence Weed, MD, 1978 America’s massive health-care system is highly complex, with its own unique language, methods, technologies, and scientific approaches, developed and ...

A Career Path Shaped by Unlimited Possibilities for Clifford A. Hudis, MD, FACP, FASCO

In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, interviewed Clifford A. Hudis, MD, FACP, FASCO, ASCO’s Chief Executive Officer. Prior to his current position, Dr. Hudis served in a variety of roles at ASCO, including President during ASCO’s 50th anniversary...

California Researchers Receive $4.5 Million to Develop Immunotherapies in Head and Neck Cancer

RESEARCHERS AT LA JOLLA INSTITUTE for Immunology and University of California (UC), San Diego, have been awarded $4.5 million as part of the National Cancer Institute’s Cancer Moonshot initiative. The funding will support research to develop new and improved immunotherapeutic options for patients...

issues in oncology
immunotherapy

The Abscopal Effect: A Reemerging Field of Interest

For the past 50 years or more, oncologists have designed their treatment plans around the three pillars: surgery, chemotherapy, and radiation. Now, with a series of recent successes, immunotherapy is rapidly reemerging as the fourth pillar in the oncologic armamentarium. Despite major advancements...

lymphoma

FDA Expands Approved Use of Brentuximab Vedotin in Some Types of PTCL

ON NOVEMBER 16, 2018, the U.S. Food and Drug Administration (FDA) expanded the approved use of brentuximab vedotin (Adcetris) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL)—adults with previously untreated systemic anaplastic...

2018 San Antonio Breast Cancer Symposium Award Winners Announced

THE SAN ANTONIO Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR) will honor three researchers for their work in breast cancer at the upcoming 2018 SABCS in December. They are Ian Smith, MD, FRCP, FRCPE, who will receive the SABCS William L. McGuire Memorial...

multiple myeloma

FDA Approves Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

ON NOVEMBER 6, 2018, following Priority Review, the U.S. Food and Drug Administration (FDA) approved elotuzumab (Empliciti) injection for intravenous use in combination with pomalidomide (Pomalyst) and dexamethasone for the treatment of adult patients with multiple myeloma who have received at...

New Leadership Elected to ASH Executive Committee

THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) announced the election of four new members to its Executive Committee for terms beginning after the 2018 ASH Annual Meeting & Exposition in December. Martin S. Tallman, MD, will serve a 1-year term as Vice President, followed by successive terms as...

FDA Approves Glasdegib for Patients With Newly Diagnosed AML Who Cannot Undergo Intensive Chemotherapy

Today, the U.S. Food and Drug Administration (FDA) approved glasdegib (Daurismo) tablets to be used in combination with low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or with comorbidities that may preclude the use of ...

Chanita Hughes-Halbert, PhD, Receives AACR Distinguished Lecture on the Science of Cancer Health Disparities

Chanita Hughes-Halbert, PhD, is the recipient of the 2018 American Association for Cancer Research (AACR) Distinguished Lecture on the Science of Cancer Health Disparities, funded by Susan G. Komen. She was honored during the 11th AACR Conference on the Science of Cancer Health Disparities in...

issues in oncology

Patients With Cancer in Rural America Remain Underserved

Despite growing national awareness of health-care inequities, the plight of rural Americans diagnosed with cancer has persistently remained inadequate. Speaking with The ASCO Post, Jan Probst, PhD, Professor at the Arnold School of Public Health, University of South Carolina, Columbia, noted, “We...

hematologic malignancies
leukemia

Duvelisib in Resistant Chronic Lymphocytic Leukemia: Expanding the Treatment Armamentarium

The phase III DUO trial, reported by Flinn et al and reviewed in this issue of The ASCO Post, has led to the U.S. Food and Drug Administration (FDA) approval of a novel B-cell receptor (BCR) kinase inhibitor, duvelisib (Copiktra), which targets phosphoinositide 3-kinase (PI3K)-δ/γ in patients...

pain management
supportive care

Parenteral Opioid Shortage Threatens Appropriate Pain Care for Patients With Cancer

In response to the opioid-overdose epidemic, several measures have been put in place, such as the reclassification of hydrocodone as a Schedule II opioid and new requirements for physician review of prescription drug–monitoring program databases in most states. Moreover, the Surgeon General and...

issues in oncology

NCI Awards Grant to Team at Baylor to Establish Center to Focus on Cancer Health Disparities

As part of the Beau Biden Cancer Moonshot initiative, the National Cancer Institute has awarded $6.3 million to Nicholas Mitsiades, MD, of the Baylor College of Medicine, and a collaborative team at Baylor College of Medicine to establish a Minority Patient-Derived Xenograft Development and Trial...

global cancer care

UPMC Opens New Radiotherapy Center in Italy

The University of Pittsburg Medical Center (UPMC) recently announced the opening of a new radiotherapy center in Villa Maria, Italy, which will become part of the UPMC Hillman Cancer Center network when it opens to patients later this year. The new center, named the UPMC Hillman Cancer Center at...

Oncologist’s Research Recognized by Radiation Oncology Institute

Amar Kishan, MD, Assistant Professor of Radiation Oncology and a member of the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center, will receive the 2018 Publication Award from the Radiation Oncology Institute in recognition of a study highlighting the value of...

issues in oncology

Inflammation, DNA Damage, and Cancer

The link between inflammation and cancer is a field of growing interest in the oncology community. Biologists have theorized that simultaneous DNA damage and cell division during inflammation could lead to cancer. To shed light on this important issue, The ASCO Post recently spoke with Jennifer...

Johns Hopkins Medicine Appoints Allen Kachalia, MD, JD, to Leadership Positions

Allen Kachalia, MD, JD, will be appointed Director of the Armstrong Institute for Patient Safety and Quality and Senior Vice President of Patient Safety and Quality for Johns Hopkins Medicine, starting December 1. During his nearly 20-year career in medicine, Dr. Kachalia has served in a variety...

hematologic malignancies
lymphoma
leukemia

Leukemia & Lymphoma Society Receives Funding for New Grants

The Leukemia & Lymphoma Society recently announced a $1,175,000 commitment by the Schwartz Ward Family Foundation of Chicago to support two research initiatives. These funds will support two grants in the society’s Career Development Program: Christiane Querfeld, MD, PhD, of City of Hope, is...

solid tumors
hepatobiliary cancer

Global Liver Institute Supports More Frequent Liver Cancer Screening

When detected early, liver cancer is highly treatable and, in many cases, curable, yet the number of new cases of liver cancer in the United States has increased by 43% in the past 16 years, whereas the incidence of other cancers is on the decline. This past October, during Liver Cancer Awareness...

lung cancer

FDA Approves Lorlatinib for Second- or Third-Line Treatment of ALK-Positive Metastatic NSCLC

On November 2, 2018, the U.S. Food and Drug Administration granted accelerated approval to lorlatinib (Lorbrena) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC) whose disease has progressed on crizotinib (Xalkori) and at least one other ALK ...

prostate cancer
issues in oncology

Undertreatment of High-Risk Prostate Cancer in Latino Men

New research by Lichtensztajn et al in JNCCN—Journal of the National Comprehensive Cancer Network examined disparities in care for Latino men with prostate cancer. A team of researchers from UCSF Helen Diller Family Comprehensive Cancer Center, Stanford Cancer Institute, and...

leukemia
immunotherapy

Azacitidine Plus Nivolumab in Relapsed or Refractory AML

A combination of the chemotherapy drug azacitidine with the immune checkpoint inhibitor nivolumab (Opdivo) demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia (AML), according to findings from a phase II study published...

breast cancer

Quality of Life With Postmastectomy Radiotherapy vs No Radiotherapy in Intermediate-Risk Breast Cancer

In a 2-year follow-up of the phase III SUPREMO trial reported in The Lancet Oncology, Galina Velikova, PhD, of the Leeds Cancer Centre, St. James’s University Hospital, United Kingdom, and colleagues found worse chest wall symptoms in women with intermediate-risk breast cancer who did vs did not...

prostate cancer

ASTRO/ASCO/AUA Guideline for Early-Stage Prostate Cancer Supports Use of Hypofractionated Radiotherapy

Three prominent medical organizations have issued a new clinical guideline for physicians treating men with early-stage prostate cancer using external-beam radiation therapy (EBRT). Developed by a panel of experts from the American Society for Radiation Oncology (ASTRO), ASCO, and the American...

Atlantic Health System Announces Collaboration to Further Patient Access to Innovative Cancer Therapies

The Atlantic Health System, an integrated health-care delivery system, recently announced a partnership with the Translational Genomics Research Institute, an affiliate of City of Hope, and Origin Commercial Ventures to create a new platform to deliver economically viable immunotherapies and other...

issues in oncology

Nosayaba Osazuwa-Peters, MPH, PhD, on Suicide Among Male Patients With Cancer: Study Findings

Nosayaba Osazuwa-Peters, MPH, PhD, of St. Louis University, discusses study findings on married cancer survivors with advanced stage disease who were less likely to die by suicide, highlighting the value of supportive care in cancer survivorship (Abstract 181).

Heidi Nelson, MD, FACS, Named Medical Director of ACS Cancer Programs

The American College of Surgeons (ACS) announced that Heidi Nelson, MD, FACS, a colorectal surgeon at the Mayo Clinic in Rochester, Minnesota, will be joining the ACS Division of Research and Optimal Patient Care (DROPC) as Medical Director of Cancer Programs. Dr. Nelson comes to the ACS from her...

issues in oncology
immunotherapy
symptom management

Allison S. Betof Warner, MD, PhD, on Managing Immune-Related Adverse Events: Incorporating Guidelines

Allison S. Betof Warner, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the rationale for immunotherapy and combination treatments, identifying the agents that lead to toxicities, and ways to manage them.

issues in oncology
pain management

Charles von Gunten, MD, PhD, on Protecting Opioid Access for Patients in Need

Charles von Gunten, MD, PhD, of OhioHealth, discusses the critical need for opioids to manage cancer pain as well as the myth of addiction, which may impede best care.

Advertisement

Advertisement



;
Advertisement